Fluphenazine
Fluphenazine (fluphenazine) is a small molecule pharmaceutical. Fluphenazine was first approved as Prolixin decanoate on 1982-01-01. It is used to treat psychotic disorders and schizophrenia in the USA. The pharmaceutical is active against D(2) dopamine receptor. In addition, it is known to target D(1A) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 7, D(1B) dopamine receptor, 5-hydroxytryptamine receptor 6, and histamine H1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| mental disorders | D001523 |
Trade Name
FDA
EMA
Fluphenazine (discontinued: Fluphenazine, Permitil, Prolixin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Fluphenazine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PROLIXIN | Bristol Myers Squibb | N-012145 DISCN | 1982-01-01 | 1 products, RLD |
| PROLIXIN | Bristol Myers Squibb | N-011751 DISCN | 1982-01-01 | 5 products |
| PERMITIL | Merck & Co | N-016008 DISCN | 1982-01-01 | 1 products |
| PERMITIL | Merck & Co | N-012419 DISCN | 1982-01-01 | 1 products |
| PERMITIL | Merck & Co | N-012034 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| fluphenazine decanoate | ANDA | 2025-03-20 |
| fluphenazine hydrochloride | ANDA | 2025-10-01 |
| fluphenazine hydrochoride | ANDA | 2025-09-18 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| schizophrenia | EFO_0000692 | D012559 | F20 |
| psychotic disorders | — | D011618 | F20.81 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2680 | Injection, fluphenazine decanoate, up to 25 mg |
Clinical
Clinical Trials
18 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | 1 | 2 | 4 | 3 | 10 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | 1 | 2 | 3 |
| Schizophrenia spectrum and other psychotic disorders | D019967 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vomiting | D014839 | — | R11.1 | — | — | 1 | — | — | 1 |
| Dementia | D003704 | EFO_0003862 | F03 | — | — | 1 | — | — | 1 |
| Psychophysiologic disorders | D011602 | — | F45.9 | — | — | 1 | — | — | 1 |
| Depression | D003863 | — | F33.9 | — | — | 1 | — | — | 1 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | 1 | — | — | 1 |
| Somatoform disorders | D013001 | — | F45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Psoriasis | D011565 | EFO_0000676 | L40 | — | 2 | — | — | — | 2 |
| Multiple myeloma | D009101 | — | C90.0 | 2 | 1 | — | — | — | 2 |
| Gambling | D005715 | EFO_1001926 | F63.0 | — | 1 | — | — | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | — | 1 |
| Body weight | D001835 | EFO_0004338 | — | 1 | — | — | — | — | 1 |
| Weight gain | D015430 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 1 | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | — | — | — | 1 | 1 |
| Emergencies | D004630 | — | — | — | — | — | — | 1 | 1 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | — | — | 1 | 1 |
| Mania | D000087122 | — | F30 | — | — | — | — | 1 | 1 |
| Breast feeding | D001942 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Fluphenazine |
| INN | fluphenazine |
| Description | Fluphenazine is a member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position. It has a role as a phenothiazine antipsychotic drug, a dopaminergic antagonist and an anticoronaviral agent. It is an organofluorine compound, a member of phenothiazines and a N-alkylpiperazine. It derives from a hydride of a 10H-phenothiazine. |
| Classification | Small molecule |
| Drug class | Typical antipsychotic |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | OCCN1CCN(CCCN2c3ccccc3Sc3ccc(C(F)(F)F)cc32)CC1 |
Identifiers
| PDB | — |
| CAS-ID | 69-23-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL726 |
| ChEBI ID | 5123 |
| PubChem CID | 3372 |
| DrugBank | DB00623 |
| UNII ID | S79426A41Z (ChemIDplus, GSRS) |
Target
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Fluphenazine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 4,602 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fluphenazine decanoate, Fluphenazine hydrochloride, Fluphenazine hydrochoride
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,503 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use